Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma
A study for subjects with relapsed or refractory multiple myeloma using study drugs daratumumab, bortezomib and dexamethasone
Sponsor: Janssen Research & Development, LLC
Enrolling: Male and Female Patients
IRB Number: AAAO1956
U.S. Govt. ID: NCT02136134
Contact: Ryan Shelton: 212-304-5485 / rs3323@columbia.edu
Additional Study Information: The purpose of this study is to look at what happens (both good and bad) when daratumumab is given with two other drugs called VELCADE and dexamethasone compared to just giving those two drugs, VELCADE and dexamethasone, alone. VELCADE is also known by the name bortezomib. Giving VELCADE and dexamethasone together is standard treatment for advanced multiple myeloma and is already used in many countries. The safety of daratumumab when given with VELCADE and dexamethasone will also be studied.
This study is closed
Investigator
Suzanne Lentzsch, MD
Do You Qualify?
Have you been diagnosed with multiple myeloma? Yes No
Have you received at least 1 prior line of therapy for multiple myeloma? Yes No
Have you received daratumumab or any other anti-CD38 therapies before? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Ryan Shelton
rs3323@columbia.edu
212-304-5485
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE